SCHEMBL5780432

SCHEMBL5780432

Cc1cccc(-c2cc(=O)[nH]c3ccc(C(=O)c4ccc(Cl)cc4)cc23)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 2/20 0.52
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
CNR2 P34972 2/20 0.49
L3MBTL1 Q9Y468 2/20 0.44
FNTA P49354 4/20 0.44
FNTB P49356 4/20 0.44
LMNA P02545 2/20 0.44
CHEK1 O14757 1/20 0.43
WEE1 P30291 1/20 0.43
TNKS2 Q9H2K2 1/20 0.41
CSF1R P07333 1/20 0.41
MAPT P10636 1/20 0.40
CNR1 P21554 1/20 0.40
TP53 P04637 1/20 0.39
MAPK1 P28482 1/20 0.39
OPRK1 P41145 1/20 0.39
HTT P42858 1/20 0.39
CCR6 P51684 1/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1538310 0.89 MEN1 (0.59) RXFP1MEN1KMT2AFNTAFNTB
SCHEMBL5722642 0.86 MEN1 (0.52) RXFP1MEN1KMT2AFNTAFNTB
SCHEMBL5514658 0.85 MAPT (0.53) RXFP1MEN1KMT2AL3MBTL1FNTA
SCHEMBL5657749 0.81 MEN1 (0.52) RXFP1MEN1KMT2AFNTAFNTB
SCHEMBL11947173 0.79 MEN1 (0.60) RXFP1MEN1KMT2ACNR2L3MBTL1
SCHEMBL5782115 0.78 KMT2A (0.66) RXFP1MEN1KMT2AMAPTMAPK1
SCHEMBL5657976 0.78 MEN1 (0.51) RXFP1MEN1KMT2AFNTAFNTB
SCHEMBL5656275 0.78 MEN1 (0.48) RXFP1MEN1KMT2AFNTAFNTB
SCHEMBL5758311 0.77 LMNA (0.47) RXFP1MEN1KMT2ALMNACNR1
SCHEMBL5782390 0.77 CNR2 (0.52) MEN1KMT2ACNR2L3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7053105-B2 Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-30 US disclosed
EP-1322635-B1 FARNESYL TRANSFERASE INHIBITING QUINOLINE AND QUINAZOLINE DERIVATIVES AS FARNESYL TRANSFERASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2006-03-22 EP disclosed
US-20030203904-A1 Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2003-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030203904-A1 Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors FNTA, FNTB, RABGGTB RXFP1 2433/4885MEN1 1218/4885KMT2A 2281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.